loading
Amneal Pharmaceuticals Inc stock is traded at $7.195, with a volume of 347.12K. It is up +0.96% in the last 24 hours and down -16.88% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$7.13
Open:
$7.23
24h Volume:
347.12K
Relative Volume:
0.21
Market Cap:
$2.26B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-10.57
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+0.39%
1M Performance:
-16.88%
6M Performance:
-15.32%
1Y Performance:
+34.04%
1-Day Range:
Value
$7.135
$7.29
1-Week Range:
Value
$7.01
$7.405
52-Week Range:
Value
$5.355
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Name
Amneal Pharmaceuticals Inc
Name
Phone
908-947-3120
Name
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Employee
5,210
Name
Twitter
@amnealpharma
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
7.195 2.26B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.26 67.28B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.47 45.61B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.29 45.01B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.99 15.25B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
290.66 12.77B 2.76B 1.11B 898.10M 22.77

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-24-25 Upgrade JP Morgan Neutral → Overweight
Sep-06-24 Upgrade JP Morgan Underweight → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Mar-08-21 Upgrade Goldman Sell → Buy
Dec-14-20 Upgrade Barclays Equal Weight → Overweight
Dec-14-20 Upgrade Guggenheim Neutral → Buy
Jul-27-20 Initiated Goldman Sell
May-12-20 Upgrade Guggenheim Sell → Neutral
Dec-12-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19 Downgrade JP Morgan Neutral → Underweight
Nov-07-19 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-11-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-08-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19 Initiated Barclays Equal Weight
May-21-19 Upgrade Raymond James Mkt Perform → Strong Buy
Mar-20-19 Initiated SunTrust Buy
Mar-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Dec-14-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18 Downgrade SunTrust Buy → Hold
Aug-13-18 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18 Initiated Morgan Stanley Overweight
Jun-22-18 Initiated B. Riley FBR, Inc. Buy
View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

pulisher
Apr 18, 2025

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com

Apr 18, 2025
pulisher
Apr 17, 2025

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance

Apr 17, 2025
pulisher
Apr 15, 2025

Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq

Apr 15, 2025
pulisher
Apr 14, 2025

10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey

Apr 14, 2025
pulisher
Apr 14, 2025

Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ

Apr 14, 2025
pulisher
Apr 14, 2025

NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits

Apr 14, 2025
pulisher
Apr 11, 2025

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace

Apr 11, 2025
pulisher
Apr 11, 2025

Amneal's $1.5M Donation Makes Parkinson's Medications More Accessible for Thousands - Stock Titan

Apr 11, 2025
pulisher
Apr 08, 2025

Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph

Apr 08, 2025
pulisher
Apr 08, 2025

Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma - Clinical Oncology News

Apr 08, 2025
pulisher
Apr 08, 2025

Amneal Earnings Preview: Key Updates Coming May 2 in Q1 2025 Report - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace

Apr 07, 2025
pulisher
Apr 07, 2025

Amneal Announces New Data From Phase 3 Study - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan

Apr 07, 2025
pulisher
Apr 04, 2025

Amneal Boruzu Subcutaneous Formulation Launch - Specialty Pharmacy Continuum

Apr 04, 2025
pulisher
Apr 03, 2025

Amneal Pharmaceuticals (AMRX) Expands Coverage for Parkinson's D - GuruFocus

Apr 03, 2025
pulisher
Apr 03, 2025

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S. - BioSpace

Apr 03, 2025
pulisher
Apr 03, 2025

Amneal gets expanded coverage for Parkinson’s disease drug - Seeking Alpha

Apr 03, 2025
pulisher
Apr 03, 2025

Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson'S Disease Patients In The U.S. - marketscreener.com

Apr 03, 2025
pulisher
Apr 03, 2025

Breakthrough: Amneal's Parkinson's Drug CREXONT Secures Game-Changing Insurance Coverage - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

Amneal and Shilpa introduce Boruzu in US for cancer treatment - Yahoo Finance

Apr 02, 2025
pulisher
Apr 01, 2025

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - The Joplin Globe

Apr 01, 2025
pulisher
Apr 01, 2025

Amneal Launches BORUZU , First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire

Apr 01, 2025
pulisher
Apr 01, 2025

Groundbreaking Cancer Treatment: First Ready-Made Bortezomib Injection Hits Market - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) - Business Wire

Mar 31, 2025
pulisher
Mar 27, 2025

Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR

Mar 27, 2025
pulisher
Mar 25, 2025

Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - simplywall.st

Mar 25, 2025
pulisher
Mar 21, 2025

Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com

Mar 21, 2025
pulisher
Mar 19, 2025

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha

Mar 19, 2025
pulisher
Mar 17, 2025

Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider

Mar 17, 2025
pulisher
Mar 12, 2025

Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace

Mar 11, 2025
pulisher
Mar 10, 2025

Amneal to Participate at Upcoming Investor Conference - WICZ

Mar 10, 2025
pulisher
Mar 08, 2025

Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 08, 2025

Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Canada

Mar 08, 2025
pulisher
Mar 07, 2025

Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView

Mar 07, 2025

Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$8.64
price up icon 1.71%
$27.39
price up icon 0.81%
$101.32
price up icon 0.62%
$7.66
price up icon 0.92%
$102.22
price up icon 0.76%
$289.83
price up icon 1.60%
Cap:     |  Volume (24h):